Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial

NCT07846865 on ClinicalTrials.gov · last registry update 2026-09-29

An unusually large phase 2/phase 3: 256 participants, more than double the 60 typical for the stage. Due to report 1 December 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Breathing Disturbance Index (BDI). Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity and sleep apnea, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status: NOT_YET_RECRUITING
Phase: P2/P3
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Woolcock Institute of Medical Research
Sponsor type: Other
Enrollment: 256
Started: 2026-10-01
Primary completion: 2028-12-01 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Detected	Change	Detail
2026-09-29	First seen in registry	Registered as NOT_YET_RECRUITING, P2/P3

Primary outcome

Breathing Disturbance Index (BDI)

Conditions studied

Sleep Apnoea · Obesity & Overweight · Sleep Apnea Syndrome, Obstructive

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.